Edding Genor Group Holdings Limited (FRA:67N0)

Market Cap	749.59M
Revenue (ttm)	302.90M -2.3%
Net Income	48.62M +2.9%
EPS	0.03 +1.0%
Shares Out	n/a
PE Ratio	15.42
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	68
Open	0.3680
Previous Close	0.3580
Day's Range	0.3680 - 0.3680
52-Week Range	0.2060 - 0.5700
Beta	n/a
RSI	69.37
Earnings Date	Mar 27, 2026

About FRA:67N0

Edding Genor Group Holdings Limited, together with its subsidiaries, engages in the research, development, manufacturing, and distribution of biopharmaceutical products in China, the United States, and internationally. The company offers GB491, a differentiated CDK4/6 inhibitor for advanced or metastatic breast cancer; GB261, a novel CD3/CD20 bispecific antibody which is in clinical development for autoimmune diseases; and GB263T and GB268, tri-specific antibody candidates which are in preclinical and early clinical stages. It also provides Van...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2001
• Employees: 1,545
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 67N0

Financial Performance

Financial numbers in CNY